Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-11-06
2000-09-05
Travers, Russell
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514380, 514307, A61K 3142, A61K 3147
Patent
active
061143677
ABSTRACT:
This invention relates to isoxazoline compounds which are inhibitors of tumor necrosis factor (TNF). The isoxazoline compounds are useful for inhibiting TNF in a mammal in need thereof and in the treatment or alleviation of inflammatory conditions or disease, including but not limited to rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and inflammatory bowel disease, sepsis, septic shock, tuberculosis, graft versus host disease and cachexia associated with AIDS or cancer. This invention also relates to pharmaceutical compositions useful therefor comprising such compounds.
REFERENCES:
Spooner et al, Clinical Immunology & Immunopathology vol. 62(1) pp. S11-S17, 1992.
Brennan et al, Lancet Jul. 29, 1989 pp. 244-247.
Cohan Victoria Lee
Kleinman Edward Fox
Benson Gregg C.
Goddard Carl J.
Pfizer Inc
Richardson Peter C.
Travers Russell
LandOfFree
Isoxazoline compounds as inhibitors of TNF release does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoxazoline compounds as inhibitors of TNF release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoxazoline compounds as inhibitors of TNF release will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2212553